Scarica l'app Stockscreener
35.60
1.87%
-0.68
Dopo l'orario di chiusura:
35.72
0.12
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.28
Aprire:
$35.9
Volume 24 ore:
1.56M
Relative Volume:
0.84
Capitalizzazione di mercato:
$3.19B
Reddito:
$333.87M
Utile/perdita netta:
$-169.00M
Rapporto P/E:
-17.45
EPS:
-2.04
Flusso di cassa netto:
$-157.30M
1 W Prestazione:
-6.83%
1M Prestazione:
+3.82%
6M Prestazione:
+132.68%
1 anno Prestazione:
+87.37%
Intervallo 1D:
$35.33
$36.59
Intervallo di 1 settimana:
$34.50
$40.75
Portata 52W:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Confronta TVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
35.60 | 3.25B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
How Travere Therapeutics Inc. stock performs in weak economyOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Travere Therapeutics Inc. stock maintain momentum in 2025Bear Alert & Verified Chart Pattern Signals - ulpravda.ru
How Travere Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Why Travere Therapeutics Inc. stock could benefit from AI revolutionMarket Trend Summary & Technical Buy Zone Confirmations - ulpravda.ru
Will Travere Therapeutics Inc. stock remain a Wall Street favorite - ulpravda.ru
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears - TechStock²
How Travere Therapeutics Inc. stock reacts to bond yields2026 world cup usa national team round of 16 goalkeepers possession football tactical prediction breakdown - ulpravda.ru
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.1%Time to Sell? - MarketBeat
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - MarketScreener
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors - Chartmill
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date - ts2.tech
Price-Driven Insight from (TVTX) for Rule-Based Strategy - Stock Traders Daily
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% Following Insider Selling - MarketBeat
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shift From Loss To Profit - 富途牛牛
Travere Therapeutics Insider Sold Shares Worth $2,406,180, According to a Recent SEC Filing - MarketScreener
Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 4,980 Shares - MarketBeat
Inrig Jula, chief medical officer of Travere, sells $630,004 in TVTX - Investing.com Canada
Travere therapeutics (TVTX) SVP Calvin sells $296k in stock By Investing.com - Investing.com Canada
Travere therapeutics (TVTX) chief research officer sells $2.4m in stock - Investing.com Canada
Heerma, Travere therapeutics CCO, sells $199k in TVTX stock By Investing.com - Investing.com Canada
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells 7,402 Shares of Stock - MarketBeat
Travere Therapeutics Executives Sell Shares - TradingView — Track All Markets
Why Travere Therapeutics stock popped by nearly 14% on Wednesday - MSN
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Traders Buy Large Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally - ts2.tech
Voya Investment Management LLC Acquires 27,133 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? - Yahoo Finance
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom - Yahoo Finance
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI - Yahoo! Finance Canada
Travere Stock (+14%): FDA Catalyst Speculation Ignites Rally - Trefis
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - Finviz
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday - The Motley Fool
Travere Therapeutics Inducement Grants: Market Anticipations - StocksToTrade
Is Travere Therapeutics Stock a Hidden Gem? - timothysykes.com
Travere Therapeutics stock gains as FDA messaging on proteinuria endpoint boosts Filspari approval hopes - Investing.com Australia
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets - ts2.tech
Travere Therapeutics (TVTX) Shares Surge Over 16% - GuruFocus
Travere Therapeutics (TVTX) Surges on Positive FDA Update - GuruFocus
Travere Therapeutics Expands with New Employee Stock Grants - timothysykes.com
Travere Therapeutics (TVTX) Sees a Significant 13.2% Surge - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week HighHere's Why - MarketBeat
Travere Therapeutics stock hits 52-week high at 37.76 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.76 USD - Investing.com
Assenagon Asset Management S.A. Has $2.23 Million Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
The Technical Signals Behind (TVTX) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is Travere Therapeutics Inc. stock a safe buy before earningsJuly 2025 PreEarnings & Consistent Growth Stock Picks - Улправда
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):